Evaluation of Efficacy and Safety of Subcutaneous Acetaminophen (APAPSubQ)
Primary Purpose
Pain, Fever, Drug Effect
Status
Completed
Phase
Phase 2
Locations
Lebanon
Study Type
Interventional
Intervention
Acetaminophen
Sponsored by
About this trial
This is an interventional other trial for Pain focused on measuring Acetaminophen, Palliative Care, Infusions, Subcutaneous, Treatment Outcome, Geriatrics, Gerontology
Eligibility Criteria
Inclusion Criteria:
- Patients seen by the Palliative Care Consultation Team, patients admitted in the Palliative Care Unit, or Geriatric patients (patients aged 65 and older) in participating centers in Lebanon
- Presence of pain or fever necessitating the administration of Paracetamol
- Absence of an Intravenous Line
Sites / Locations
- Hotel-Dieu de France
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
SC Acetaminophen
Arm Description
Palliative Care or Geriatric Patients who receive subcutaneous Acetaminophen for pain or fever relief
Outcomes
Primary Outcome Measures
Change in Numerical Rating Scale pain scores for conscious and cooperative patients
This outcome measures the decrease in pain scores between t0 (right before acetaminophen administration) and t60 minutes using the Numerical Rating Scale in conscious and cooperative patients, where 10/10 is the worst imaginable pain and 0/10 is no pain at all.
A Minimal Clinically Important Difference (MCID) of 2/10 is set to define efficacy.
Change on Algoplus Pain Scale for patients with verbal communication difficulties
This outcome measures the decrease in pain scores between t0 (right before acetaminophen administration) and t60 minutes using Algoplus Scale, a behavioural rating scale for acute pain for patients with verbal communication difficulties. A score of 2 or above diagnoses pain with 87% sensitivity and 80% specificity.
The scale evaluates facial expressions, look, complaints, body position and atypical behaviours of patients with verbal communication difficulties.
Each item marked "yes" is awarded one point and the total across all the items gives a total score out of 5.
Efficacy is defined as a decrease of the score to less than 2/5.
Change in temperature measurement
Decrease in temperature measurement. A Minimal Clinically Important Difference (MCID) of 0.5 degrees Celsius is set to define efficacy.
Appearance of local side effects
Any local side effect is reported, including:
edema,
induration,
erythema,
tenderness,
warmth,
abcess,
necrosis
Secondary Outcome Measures
Early effect on pain in conscious and cooperative patients
To evaluate if any early effect on pain is measurable, this outcome measures the pain scores at t30 minutes using the Numerical Rating Scale in conscious and cooperative patients, where 10/10 is the worst imaginable pain and 0/10 is no pain at all.
Sustained effect on pain in conscious and cooperative patients
To evaluate if the effect on pain is sustained over time, this outcome measures the pain scores at t180 minutes using the Numerical Rating Scale in conscious and cooperative patients, where 10/10 is the worst imaginable pain and 0/10 is no pain at all.
Early effect on pain in patients with verbal communication difficulties
To evaluate if any early effect on pain is measurable, this outcome measures the pain scores at t60 minutes and t180 minutes using Algoplus Scale, a behavioural rating scale for acute pain for patients with verbal communication difficulties. A score of 2 or above diagnoses pain with 87% sensitivity and 80% specificity.
The scale evaluates facial expressions, look, complaints, body position and atypical behaviours of patients with verbal communication difficulties.
Each item marked "yes" is awarded one point and the total across all the items gives a total score out of 5.
Sustained effect on pain in patients with verbal communication difficulties
To evaluate if the effect on pain is sustained over time, this outcome measures the pain scores at t180 minutes using Algoplus Scale, a behavioural rating scale for acute pain for patients with verbal communication difficulties. A score of 2 or above diagnoses pain with 87% sensitivity and 80% specificity.
The scale evaluates facial expressions, look, complaints, body position and atypical behaviours of patients with verbal communication difficulties.
Each item marked "yes" is awarded one point and the total across all the items gives a total score out of 5.
Early effect on fever
To evaluate if any early effect on fever is measurable, temperature is measured at t30 minutes.
Sustained effect on fever
To evaluate if the effect on fever is sustained over time, temperature is measured at t180 minutes
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03635684
Brief Title
Evaluation of Efficacy and Safety of Subcutaneous Acetaminophen
Acronym
APAPSubQ
Official Title
Evaluation of Efficacy and Safety of Subcutaneous Acetaminophen in Geriatrics and Palliative Care
Study Type
Interventional
2. Study Status
Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
May 17, 2018 (Actual)
Primary Completion Date
June 1, 2020 (Actual)
Study Completion Date
June 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Saint-Joseph University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
Subcutaneous perfusion is an underused technique, the effectiveness of which has been demonstrated.
A number of drugs of different therapeutic classes, including morphine, have a good level of scientific evidence for use by this route.
Subcutaneous Acetaminophen injection is being used in some medical centers, mainly in Europe, despite the lack of definite evidence on its efficacy.
This study aims to quantify the degree of effectiveness of subcutaneous Acetaminophen infusions for pain or fever in Geriatrics and Palliative Care, as well as determining its safety.
Detailed Description
Subcutaneous perfusion is an underused technique, the effectiveness of which has been demonstrated. It is mainly used in Palliative Care and Geriatrics when a venous line is not available. It is a simple and comfortable technique that allows to administer solutes and / or medications continuously or discontinuously in the subcutaneous tissue.
A number of drugs of different therapeutic classes, including morphine, have a good level of scientific evidence for use by this route.
Subcutaneous Acetaminophen injection is being used in some medical centers, mainly in Europe, despite the lack of definite evidence on its efficacy. It is sometimes accused of causing pain at the injection site; it seems that this is not the case if it is infused slowly, over 20 minutes to 30 minutes. There is no report of serious local effects.
The consultation palliative care team at Hôtel-Dieu de France (HDF) has used subcutaneous Acetaminophen infusions repeatedly without adverse effects since January 2014.
This study aims to quantify the degree of effectiveness of subcutaneous Acetaminophen infusions for pain or fever in Geriatrics and Palliative Care, as well as determining its safety.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Fever, Drug Effect, Drug Reaction
Keywords
Acetaminophen, Palliative Care, Infusions, Subcutaneous, Treatment Outcome, Geriatrics, Gerontology
7. Study Design
Primary Purpose
Other
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
31 (Actual)
8. Arms, Groups, and Interventions
Arm Title
SC Acetaminophen
Arm Type
Experimental
Arm Description
Palliative Care or Geriatric Patients who receive subcutaneous Acetaminophen for pain or fever relief
Intervention Type
Drug
Intervention Name(s)
Acetaminophen
Other Intervention Name(s)
Perfalgan, Paracetamol Macopharma
Intervention Description
Subcutaneous infusion of Acetaminophen over 20 to 30 minutes, with evaluation of:
local side effects;
pain and/or fever;
at time of infusion, after 30 minutes, 60 minutes and 180 minutes.
Primary Outcome Measure Information:
Title
Change in Numerical Rating Scale pain scores for conscious and cooperative patients
Description
This outcome measures the decrease in pain scores between t0 (right before acetaminophen administration) and t60 minutes using the Numerical Rating Scale in conscious and cooperative patients, where 10/10 is the worst imaginable pain and 0/10 is no pain at all.
A Minimal Clinically Important Difference (MCID) of 2/10 is set to define efficacy.
Time Frame
60 minutes
Title
Change on Algoplus Pain Scale for patients with verbal communication difficulties
Description
This outcome measures the decrease in pain scores between t0 (right before acetaminophen administration) and t60 minutes using Algoplus Scale, a behavioural rating scale for acute pain for patients with verbal communication difficulties. A score of 2 or above diagnoses pain with 87% sensitivity and 80% specificity.
The scale evaluates facial expressions, look, complaints, body position and atypical behaviours of patients with verbal communication difficulties.
Each item marked "yes" is awarded one point and the total across all the items gives a total score out of 5.
Efficacy is defined as a decrease of the score to less than 2/5.
Time Frame
60 minutes
Title
Change in temperature measurement
Description
Decrease in temperature measurement. A Minimal Clinically Important Difference (MCID) of 0.5 degrees Celsius is set to define efficacy.
Time Frame
60 minutes
Title
Appearance of local side effects
Description
Any local side effect is reported, including:
edema,
induration,
erythema,
tenderness,
warmth,
abcess,
necrosis
Time Frame
at the time of perfusion, after 30 minutes, 60 minutes and 180 minutes, and one day after line removal
Secondary Outcome Measure Information:
Title
Early effect on pain in conscious and cooperative patients
Description
To evaluate if any early effect on pain is measurable, this outcome measures the pain scores at t30 minutes using the Numerical Rating Scale in conscious and cooperative patients, where 10/10 is the worst imaginable pain and 0/10 is no pain at all.
Time Frame
30 minutes
Title
Sustained effect on pain in conscious and cooperative patients
Description
To evaluate if the effect on pain is sustained over time, this outcome measures the pain scores at t180 minutes using the Numerical Rating Scale in conscious and cooperative patients, where 10/10 is the worst imaginable pain and 0/10 is no pain at all.
Time Frame
180 minutes
Title
Early effect on pain in patients with verbal communication difficulties
Description
To evaluate if any early effect on pain is measurable, this outcome measures the pain scores at t60 minutes and t180 minutes using Algoplus Scale, a behavioural rating scale for acute pain for patients with verbal communication difficulties. A score of 2 or above diagnoses pain with 87% sensitivity and 80% specificity.
The scale evaluates facial expressions, look, complaints, body position and atypical behaviours of patients with verbal communication difficulties.
Each item marked "yes" is awarded one point and the total across all the items gives a total score out of 5.
Time Frame
30 minutes
Title
Sustained effect on pain in patients with verbal communication difficulties
Description
To evaluate if the effect on pain is sustained over time, this outcome measures the pain scores at t180 minutes using Algoplus Scale, a behavioural rating scale for acute pain for patients with verbal communication difficulties. A score of 2 or above diagnoses pain with 87% sensitivity and 80% specificity.
The scale evaluates facial expressions, look, complaints, body position and atypical behaviours of patients with verbal communication difficulties.
Each item marked "yes" is awarded one point and the total across all the items gives a total score out of 5.
Time Frame
180 minutes
Title
Early effect on fever
Description
To evaluate if any early effect on fever is measurable, temperature is measured at t30 minutes.
Time Frame
30 minutes
Title
Sustained effect on fever
Description
To evaluate if the effect on fever is sustained over time, temperature is measured at t180 minutes
Time Frame
180 minutes
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients seen by the Palliative Care Consultation Team, patients admitted in the Palliative Care Unit, or Geriatric patients (patients aged 65 and older) in participating centers in Lebanon
Presence of pain or fever necessitating the administration of Paracetamol
Absence of an Intravenous Line
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joe El Khoury, MD
Organizational Affiliation
Hotel-Dieu de France
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hotel-Dieu de France
City
Beirut
Country
Lebanon
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Evaluation of Efficacy and Safety of Subcutaneous Acetaminophen
We'll reach out to this number within 24 hrs